Chemed (CHE) Liabilities and Shareholders Equity (2009 - 2026)

Chemed (CHE) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 11.05% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $6.4 billion (down 7.02% YoY), while the FY2025 annual figure was $1.5 billion, down 7.81% from the prior year.
• Liabilities and Shareholders Equity came in at $1.5 billion for Q1 2026 at Chemed, roughly flat from $1.5 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.8 billion in Q3 2024, with the low at $1.3 billion in Q1 2022.
• Average Liabilities and Shareholders Equity over 5 years is $1.6 billion, with a median of $1.6 billion recorded in 2023.
• Across the five-year window, Liabilities and Shareholders Equity gained 20.71% in 2024 and fell 11.05% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.4 billion in 2022, then grew by 15.68% to $1.7 billion in 2023, then rose by 0.03% to $1.7 billion in 2024, then slipped by 7.81% to $1.5 billion in 2025, then dropped by 0.15% to $1.5 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.5 billion, $1.5 billion, and $1.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.